
Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
This Underrated Italian City Boasts Indulgent Food & Captivating Views For A Romantic Escape
Find the Abilities Required for Advanced Advertising Position
Live long and loiter: Why NASA's ESCAPADE probes will wait a year in space before heading to Mars
Lockheed Martin opens new hypersonic weapons facility
French and Malaysian authorities are investigating Grok for generating sexualized deepfakes
False fuel prices in fabricated graphics circulate in Malaysia as Iran war continues
The most effective method to Keep up with Proficient Handshakes in a Computerized World
Defense Minister Katz finally condemns Jewish extremist violence against Palestinians
Ten Awesome Authentic Realities That Will Leave You Interested













